Ticagrelor Versus Cilostazol in Ischemic Stroke
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
Along with the current clinical trial, the efficacy and safety of ticagrelor and aspirin administered within the first 24 hours of first-ever ischemic stroke compared to cilostazol and aspirin were assessed through NIHSS, mRS, and possible adverse effects.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• the investigators included both genders with eligible ages ranging between 18-75 years, with the first-ever presentation with acute minor ischemic stroke or TIA who received antiplatelet treatment within the first 24 hours of the onset of ischemic stroke. Patients are not eligible for rt-PA treatment
Locations
Other Locations
Egypt
Kafr Elsheikh University Hospital
RECRUITING
Kafr Ash Shaykh
Contact Information
Primary
mohamed G Zeinhom, MD
mohamed_gomaa@med.kfs.edu.eg
2001009606828
Backup
sherihan R. ahmed, MD
sherihanrezk2016@gmail.com
2001113432342
Time Frame
Start Date: 2023-12-01
Estimated Completion Date: 2024-12-30
Participants
Target number of participants: 900
Treatments
Active_comparator: ticagrelor arm
the ticagrelor arm will receive (180 mg loading dose during the first 12 hours of stroke onset followed by 90 mg b.i.d from the 2nd to the 90th day) and aspirin at a loading dose of 75 to 300 mg, followed by 75 mg daily for 21 days.
Active_comparator: cilostazol arm
The cilostazol arm will receive (a 200mg loading dose during the first 12 hours of stroke onset, followed by 100mg twice daily from the 2nd day to the 90th day) and aspirin at a loading dose of 75 to 300 mg, followed by 75 mg daily for 21 days.
Related Therapeutic Areas
Sponsors
Leads: Kafrelsheikh University